ECE1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population carrying a targeted disruption of the ECE1 gene in the human NCI-H1975 lung adenocarcinoma cell line. This knockout pool abolishes expression of endothelin-converting enzyme-1, the metalloprotease responsible for converting inactive big endothelin-1 to mature endothelin-1 (ET-1). The polyclonal format provides a heterogeneous population that captures diverse knockout events, suitable for bulk functional analyses.
The NCI-H1975 parental line is a well-characterized non-small cell lung cancer (NSCLC) model derived from a female adenocarcinoma patient. It harbors endogenous EGFR L858R and T790M mutations, the latter associated with resistance to first-generation EGFR tyrosine kinase inhibitors. These features make NCI-H1975 a key platform for studying EGFR-mutant NSCLC biology and for evaluating signaling networks that sustain tumor growth.
ECE1 encodes a zinc metalloprotease that also processes other vasoactive peptides such as bradykinin and substance P. The primary product, ET-1, acts on ETA and ETB G protein-coupled receptors, activating G??q/11?CPLC?¨CPKC cascades and downstream MAPK/ERK and PI3K/AKT pathways. ECE1 expression is regulated by TGF-??, TNF-??, and hypoxia/HIF-1??, forming feedback loops that amplify signaling.
In NCI-H1975 cells, autocrine/paracrine ET-1 signaling promotes proliferation and survival, potentially converging with oncogenic EGFR outputs. ECE1 knockout eliminates ET-1 production, uncoupling endothelin receptors from downstream effectors. This allows dissection of endothelin-specific contributions to EGFR-mutant NSCLC independently of EGFR signals, and assessment of ECE1 as a potential target.
This polyclonal knockout pool supports proliferation, migration, and invasion assays, phospho-ERK/AKT western blotting, ET-1 ELISA, and RT-qPCR confirmation of ECE1 loss. It is ideal for drug screening with endothelin receptor antagonists and for co-culture studies examining paracrine crosstalk. By integrating these approaches, researchers can delineate ECE1??s role in lung cancer and explore combinatorial therapies. For further details, contact Ascent Research.
